Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister PhenotypeANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52022-10-185OA
Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid PhaseANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52021-09-176OA
Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You GetANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52021-07-165OA
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy RegimensANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52021-01-2011OAAI
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52020-11-172OA
Building Optimal Three-Drug Combination Chemotherapy RegimensANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52020-10-2013OAAI
Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection ModelANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52018-12-0114OAAI
The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model在中空纤维感染模型中，磷霉素和美罗培南的组合对铜绿假单胞菌PAO1具有协同作用ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52018-12-0134OAAI
Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model在中空纤维感染模型中确定磷霉素对铜绿假单胞菌的动态联系指数ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52018-06-0119OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向